![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 27, 2017 9:02:21 AM
I personally would not like to be in MGMT's shoes right now. There are just too many ways they can move forward and I am hoping they make the correct choice for the long run. I do have full confidence they will, but I can only imagine how difficult this could be. The scenarios could be endless because Brilacidin is such a unique drug with just too many possible indications in it's back pocket. We could have an enormous market lighting deal in the upcoming days with some huge milestones if a single BP wants to take the reigns of B all together and does not want to share indications with others.
If B-OM proves to be anywhere around 60%-80% preventative over a 30% placebo we will see a nice deal IMO. If they mark the 80% we could see a huge deal since we would run the show and every HN patient would take B-OM for prevention.
What then for B-UP/UC? It's the same properties and will further show proof of B's magical efficacy. Will the BP want to allow some other BP to step in on BD indications (btw we could see Crohns etc...) $$$$$
What about the B-Absssi that is already just chilling and waiting for a phase 3 as discussed all weekend? That is low hanging fruit.
Move to the derma options with B - eczema, HS, acne!!! $$$$
It is just so overwhelming to think about and what does MGMT want to do? Ride in to the sunset and let BP take the reigns on many items or do they want to license out each indication and have multiple partners on B?
It will be interesting to see, but after reading all weekend the past comments on partners and putting together on when the hired Dr. B is making me smile ear to ear right now........bc I think we are very very close to the turning point where this stock will reach 20's, 30's, 40's 50's easily and keep going over the years to come. JMO
Good luck all!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM